AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2020
Apr 3, 2020
30604_dirs_2020-04-03_9a6bdee9-b6f2-4166-8301-1b75cba90557.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-04-01
Reporting Person: HENDERSON MICHAEL THOMAS (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-04-01 | Common Stock | S | 44 | $25.40 | Disposed | 170268 | Direct |
| 2020-04-01 | Common Stock | S | 1441 | $26.5084 | Disposed | 168827 | Direct |
| 2020-04-01 | Common Stock | S | 1100 | $27.5573 | Disposed | 167727 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019.
F2: Represents the weighted average sale price of the shares sold from $26.15 to $27.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
F3: Represents the weighted average sale price of the shares sold from $27.18 to $28.11 per share.